Share the post "Aarti Drugs ‘s Q3 2024-25 Latest News: Profit Rises by 21.85% YoY"
Highlights
🔹 The presented financial data is Standalone to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company’s sales declined by -4.4 % over the year, decrease in net sales/revenue by -5.26 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 576.79 %. Marginal increase in other income during this quarter, up by 2892.11%. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Aarti Drugs Limited. Notable increase of 21.85 % in net profit Year to Year, Aarti Drugs Limited’s profitability increased by 26.79 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 22.67 % Year to Year. EPS increased by 26.73 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 538.21 Cr | Rs. 543.09 Cr | Rs. 514.54 Cr | -5.26 % | -4.4 % |
| Expenses | Rs. 478.47 Cr | Rs. 483.55 Cr | Rs. 454.29 Cr | -6.05 % | -5.05 % |
| Operating Profit | Rs. 59.74 Cr | Rs. 59.54 Cr | Rs. 60.25 Cr | + 1.19 % | + 0.85 % |
| OPM % | 11.1 % | 10.96 % | 11.71 % | + 0.75 % | + 0.61 % |
| Other Income | Rs. 1.68 Cr | Rs. 0.38 Cr | Rs. 11.37 Cr | + 2892.11 % | + 576.79 % |
| Interest | Rs. 6.75 Cr | Rs. 7.17 Cr | Rs. 7.57 Cr | + 5.58 % | + 12.15 % |
| Depreciation | Rs. 11.8 Cr | Rs. 11.86 Cr | Rs. 12.02 Cr | + 1.35 % | + 1.86 % |
| Profit before tax | Rs. 42.87 Cr | Rs. 40.89 Cr | Rs. 52.03 Cr | + 27.24 % | + 21.37 % |
| Tax % | 26.24 % | 25.68 % | 25.95 % | + 0.27 % | -0.29 % |
| Net Profit | Rs. 31.62 Cr | Rs. 30.39 Cr | Rs. 38.53 Cr | + 26.79 % | + 21.85 % |
| EPS in Rs | Rs. 3.44 | Rs. 3.33 | Rs. 4.22 | + 26.73 % | + 22.67 % |
Today, we’re looking at Aarti Drugs Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a significant year-over-year sales decline of -4.4 %. However, it did see a marginal slip of -5.26 % from the previous quarter. Expenses decreased slightly by -6.05 % quarter-on-quarter, aligning with the annual decline of -5.05 %. Operating profit, while up 0.85 % compared to last year, faced a quarter-on-quarter increase of 1.19 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 0.61 %, but an expansion of 0.75 % sequentially. Other income rose by 2892.11 % compared to the last quarter, despite an annual growth of 576.79 %. Interest expenses surged remarkably by 5.58 % from the previous quarter, yet the year-over-year increase remains at a moderate 12.15 %. Depreciation costs climbed by 1.35 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 1.86 %. Profit before tax grew annually by 21.37 % but saw an increase from the preceding quarter by 27.24 %.
Tax expenses as a percentage of profits decreased slightly by -0.29 % compared to last year, with a more notable quarter-on-quarter increase of 0.27 %. Net profit rose by 21.85 % year-on-year but experienced a 26.79 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 22.67 % but a quarterly rise of 26.73 %. In summary, Aarti Drugs Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 538.21 Cr | Rs. 543.09 Cr | Rs. 514.54 Cr | -5.26 % | -4.4 % |
| Expenses | Rs. 478.47 Cr | Rs. 483.55 Cr | Rs. 454.29 Cr | -6.05 % | -5.05 % |
| Operating Profit | Rs. 59.74 Cr | Rs. 59.54 Cr | Rs. 60.25 Cr | + 1.19 % | + 0.85 % |
| Net Profit | Rs. 31.62 Cr | Rs. 30.39 Cr | Rs. 38.53 Cr | + 26.79 % | + 21.85 % |
| EPS in Rs | Rs. 3.44 | Rs. 3.33 | Rs. 4.22 | + 26.73 % | + 22.67 % |
In reviewing Aarti Drugs Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -4.4 % year-on-year, although there was a slight dip of -5.26 % from the previous quarter. Expenses decreased by -5.05 % compared to the previous year, with a decrease of -6.05 % quarter-on-quarter. Operating Profit surged by 0.85 % annually, and saw a 1.19 % increase from the last quarter.
Net Profit showed yearly increase of 21.85 %, and experienced a 26.79 % increase from the previous quarter. Earnings Per Share (EPS) rose by 22.67 % annually, however rose by 26.73 % compared to the last quarter. In essence, while Aarti Drugs Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/shareholding/49.-Money-Market-Instruments.jpg)